Prognostic Significance of HER-2 Expression in Gastric Cancer

Year 2021, Volume: 4 Issue: 2, 52 - 57, 01.05.2021

Onur Ceylan , Sevilay Özmen

https://doi.org/10.19127/bshealthscience.836510

Abstract

In gastric cancers we purposed to examine the relationship between age, gender, invasion depth, lymph node metastasis,
lymphovascular invasion, Lauren's classification, presence of perineural invasion and the expression of Human Epidermal Growth
Receptor (HER-2) by immunohistochemical (IHC) and dual-color silver-enhanced in situ hybridization (D-SISH) method. In our study,
242 gastric resection materials that were studied HER-2 by IHC and/or D-SISH method referred to our department between January
2014 and December 2017 for malignancy were included. The relationship between HER-2 expression rate and prognostic parameters
was investigated. No statistical relation was found between age and gender and HER-2 positivity in either method. No statistically
significant results were obtained between lymphovascular invasion, lymph node metastasis, presence of perineural invasion, depth of
invasion and Lauren classification, and HER-2 positivity by immunohistochemical and D-SISH method. In our study, no statistically
significant results were obtained between important prognostic parameters and HER-2 positivity with either IHC or D-SISH method. In
24.1% of the cases that were HER-2 positive by IHC, positivity was not observed with the D-SISH method. Also, 20.8% of the cases
reported as immunohistochemically uncertain (equivocal) were seen as positive by the D-SISH method. Based on all these results, we
would like to state that HER-2 positivity / negativity determined by IHC can be changed by the D-SISH method. In addition, although it
was shown in our study that HER-2 has no prognostic significance in gastric carcinomas, it is reported in studies in the literature that
the addition of Trastuzumab to chemotherapy increases survival. For this reason, we think that it would be more beneficial to apply
the IHC and D SISH method together to obtain the true HER-2 result.

Keywords

Gastric Cancer, Prognosis, HER-2

References

• Alacali M. 2012. Mide kanseri, mide kanseri taramaları ve mide kanserinden korunma. Ankara Med J, 12(4): 195-198.
• Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. 2000. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18(11): 2201-2209.
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Satoh T. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet, 376(9742): 687-697.
• Bernard W. 2014. World cancer report. Stewart and Christopher P. Wild. ISBN 978-92-832-0429-9.
• Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Lillemoe KD. 2005. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointestinal Surg, 9(5): 718-725.
• Diniz Ünlü AG, Irkkan Ç, Kelten C, Özekinci S. 2015. HER2 değerlendirmesindeki ipucu ve tuzaklar. İzmir Tepecik Eğt Hast Derg, 25(1): 7-12.
• Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Falcone A. 2011. Anti-HER agents in gastric cancer: from bench to bedside. Nature Rev Gastroenterol & Hepatol, 8(7): 369.
• Göçmen E, Kocaoğlu H. 2000. Mide kanseri epidemiyolojisi. Türkiye Klin Cerrahi Derg, 5(4): 161-162.
• Grávalos C, Gómez-Martín C, Rivera F, Alés I, Queralt B, Márquez A, Sastre J. 2011. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Translational Oncol, 13(3): 179.
• Gültekin M, Boztaş G. 2014. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, 43: 12-32.
• Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, Kim W, Henkel T. 2008. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52(7): 797-805.
• Junior PNA, Neto RA, Forones NM. 2016. HER2 expression as a prognostic factor in metastatic gastric cancer. Arquivos de Gastroenterol, 53(2): 62-67.
• Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Park YS. 2011. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Annals of Surg Oncol, 18(10): 2833-2840.
• Koh YW, Lee HJ, Lee JW, Kang J, Gong G. 2011. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Modern Pathol, 24(6): 794-800.
• Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Sun Z. 2017. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol, 15(1): 1-7.
• Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, de Mello RA. 2013. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World Journal of Gastroenterology: WJG, 19(38): 6383.
• Msyamboza KP, Dzamalala C, Mdokwe C, Kamiza S, Lemerani M, Dzowela T, Kathyola D. 2012. Burden of cancer in Malawi; common types, incidence and trends: national population-based cancer registry. BMC Res Notes, 5(1): 149.
• Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Bloom KJ. 2003. The Her‐2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist, 8(4): 307-325.
• Sasano H, Date F, Imatani A, Asaki S, Nagura H. 1993. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Human Pathol, 24(6): 584-589.
• Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y, Sihvo E. 2005. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncol, 16(2): 273-278.
• Uprak TK. 2014. Mide kanserlerinde HER-2 sıklığı, klinikopatolojik parametreler ve prognoz ile ilişkisi. PhD Thesis, Marmara University, İstanbul, Turkey.
• Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Fitzgibbons P. 2014. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives Pathol Lab Med, 138(2): 241-256.
• Yalçın B, Zengin N, Aydın F, İlhan M, Işıkdoğan A, Demir G. 2006. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study. Turk J Cancer, 36: 108-115.
• Yildirim S, Dandin O, Durmus M, Karapinar U, Aslan M, Gokce M, Sahin F. 2012. C-erb-B2 (Her2/neu) Expression rate and its association with clinicopathologic parameters in gastric cancer. Int J Hematol Oncol, 29(4): 156-162.
• Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Sasaki T. 1991. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 51(3): 1034-1038.